Last reviewed · How we verify

NCT03424512: GMAC

Group Metacognitive Therapy for Anxiety and Depression in Cancer Survivors

Terminated NA Last updated 29 August 2022
What this trial tests

NA trial testing Group Metacognitive Therapy in Cancer in 15 participants. Terminated before completion.

Timeline
1 April 2018
Primary endpoint
10 December 2018
10 December 2018

Quick facts

Lead sponsorUniversity of Liverpool
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment15
Start date1 April 2018
Primary completion10 December 2018
Estimated completion10 December 2018
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Liverpool

Who can join

18 and older, any sex, with Cancer or Anxiety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to test the potential of group metacognitive therapy in alleviating emotional distress in cancer survivors. The investigators aim to find out if a group based approach is acceptable to patients and feasible to deliver in a routine clinical health psychology service.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other University of Liverpool trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03424512.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing